FDA has approved Sanofi-Aventis’s Nasacort AQ for use in children aged two to five years old. The indication is for nasal symptoms associated with perennial allergic rhinitis.
The FDA will conduct trials to establish the safety of Teva’s generic version of GlaxoSmithKline’s Wellbutrin XL. The review was prompted by patients complaining of side effects after switching from the brand to the generic.
